 Andrey Soares
Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Information Interoperability | 1 | 2024 | 3 | 0.860 |
Why?
| | Carcinoma, Renal Cell | 4 | 2026 | 234 | 0.770 |
Why?
| | Computer Systems | 1 | 2022 | 56 | 0.720 |
Why?
| | Kidney Neoplasms | 4 | 2026 | 412 | 0.680 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 732 | 0.630 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 265 | 0.510 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2026 | 985 | 0.450 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2026 | 199 | 0.440 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2026 | 255 | 0.380 |
Why?
| | Electronic Health Records | 4 | 2025 | 1173 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2026 | 1953 | 0.230 |
Why?
| | Heterocyclic Compounds, 1-Ring | 1 | 2025 | 6 | 0.230 |
Why?
| | Lutetium | 1 | 2025 | 6 | 0.230 |
Why?
| | Radioisotopes | 1 | 2025 | 33 | 0.230 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2026 | 68 | 0.230 |
Why?
| | Dipeptides | 1 | 2025 | 57 | 0.230 |
Why?
| | Taxoids | 1 | 2025 | 116 | 0.220 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2025 | 53 | 0.220 |
Why?
| | Radiopharmaceuticals | 1 | 2025 | 194 | 0.220 |
Why?
| | Health Level Seven | 1 | 2024 | 2 | 0.210 |
Why?
| | Biological Products | 2 | 2024 | 252 | 0.210 |
Why?
| | Platelet Transfusion | 1 | 2024 | 80 | 0.200 |
Why?
| | Needs Assessment | 1 | 2025 | 404 | 0.190 |
Why?
| | Developing Countries | 1 | 2024 | 318 | 0.180 |
Why?
| | Computers | 1 | 2022 | 67 | 0.180 |
Why?
| | Erythrocyte Transfusion | 1 | 2024 | 231 | 0.180 |
Why?
| | Tobacco Use | 1 | 2022 | 61 | 0.170 |
Why?
| | Computer Communication Networks | 1 | 2021 | 32 | 0.170 |
Why?
| | Programming Languages | 1 | 2021 | 25 | 0.170 |
Why?
| | Tobacco Products | 1 | 2022 | 84 | 0.170 |
Why?
| | Decision Support Techniques | 1 | 2025 | 456 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2026 | 641 | 0.160 |
Why?
| | Confidentiality | 1 | 2021 | 79 | 0.160 |
Why?
| | Immunotherapy | 1 | 2025 | 653 | 0.160 |
Why?
| | Information Storage and Retrieval | 1 | 2021 | 121 | 0.160 |
Why?
| | Natural Language Processing | 1 | 2021 | 103 | 0.160 |
Why?
| | Bias | 1 | 2021 | 202 | 0.150 |
Why?
| | Transgender Persons | 1 | 2023 | 191 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2026 | 780 | 0.150 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8265 | 0.150 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 251 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2026 | 1519 | 0.140 |
Why?
| | Language | 1 | 2021 | 321 | 0.140 |
Why?
| | Aged | 10 | 2026 | 25913 | 0.140 |
Why?
| | Humans | 18 | 2026 | 144759 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2024 | 974 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2021 | 365 | 0.120 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.120 |
Why?
| | Retrospective Studies | 7 | 2026 | 17066 | 0.110 |
Why?
| | Middle Aged | 9 | 2026 | 35875 | 0.100 |
Why?
| | Male | 13 | 2026 | 72315 | 0.100 |
Why?
| | Treatment Outcome | 5 | 2026 | 11679 | 0.100 |
Why?
| | Algorithms | 1 | 2021 | 1837 | 0.100 |
Why?
| | Female | 12 | 2026 | 78271 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2168 | 0.090 |
Why?
| | Research | 1 | 2023 | 431 | 0.080 |
Why?
| | Adult | 7 | 2025 | 40449 | 0.070 |
Why?
| | Prognosis | 2 | 2026 | 4282 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2025 | 161 | 0.050 |
Why?
| | Orchiectomy | 1 | 2024 | 74 | 0.050 |
Why?
| | Brazil | 1 | 2024 | 180 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2025 | 421 | 0.050 |
Why?
| | Blood Banks | 1 | 2024 | 50 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2024 | 91 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 121 | 0.050 |
Why?
| | Common Data Elements | 1 | 2021 | 15 | 0.040 |
Why?
| | Life Style | 1 | 2024 | 479 | 0.040 |
Why?
| | Blood Platelets | 1 | 2024 | 400 | 0.040 |
Why?
| | Survival Rate | 1 | 2026 | 2089 | 0.040 |
Why?
| | Patient Participation | 1 | 2023 | 431 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 969 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2025 | 1137 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2023 | 491 | 0.040 |
Why?
| | Age Factors | 1 | 2026 | 3333 | 0.030 |
Why?
| | Erythrocytes | 1 | 2024 | 757 | 0.030 |
Why?
| | Weight Loss | 1 | 2024 | 836 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1671 | 0.030 |
Why?
| | United States | 2 | 2024 | 15966 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2117 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5408 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1694 | 0.030 |
Why?
| | Communication | 1 | 2021 | 965 | 0.030 |
Why?
| | Adolescent | 2 | 2024 | 22428 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3409 | 0.020 |
Why?
| | Registries | 1 | 2021 | 2385 | 0.020 |
Why?
| | Pregnancy | 1 | 2024 | 7190 | 0.020 |
Why?
| | Infant | 1 | 2024 | 10034 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 14105 | 0.010 |
Why?
|
|
Soares's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|